# Fluoxetine in Refractory Superior Mesenteric Artery Syndrome by Targeting Comorbid Somatic Symptom Disorder

> **NCT07115472** · NA · COMPLETED · sponsor: **Xijing Hospital of Digestive Diseases** · enrollment: 45 (actual)

## Conditions studied

- Superior Mesenteric Artery Syndrome
- Somatic Symptom Disorder (DSM-5)

## Interventions

- **DRUG:** Fluoxetine

## Key facts

- **NCT ID:** NCT07115472
- **Lead sponsor:** Xijing Hospital of Digestive Diseases
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-01
- **Primary completion:** 2024-12-01
- **Final completion:** 2025-06-01
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2025-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07115472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07115472, "Fluoxetine in Refractory Superior Mesenteric Artery Syndrome by Targeting Comorbid Somatic Symptom Disorder". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07115472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*